Stephens Investment Management Group LLC Lowers Stock Holdings in Halozyme Therapeutics, Inc. $HALO

Key Points

• Stephens Investment Management Group LLC has decreased its stake in Halozyme Therapeutics, Inc. by 3.4%, now owning approximately 1,291,977 shares worth $67.2 million.
• CEO Helen Torley sold 20,000 shares of the company, resulting in a 2.65% decrease in her ownership, while corporate insiders sold a total of 108,227 shares valued at $7.78 million over the last quarter.
• Analysts have mixed ratings on HALO, with the stock being rated as a "buy" by some firms while others recommend a "hold", reflecting uncertainty in its future performance.

Stephens Investment Management Group LLC reduced its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 3.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,291,977 shares of the biopharmaceutical company's stock after selling 44,997 shares during the quarter. Stephens Investment Management Group LLC owned 1.05% of Halozyme Therapeutics worth $67,209,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of HALO. Wealth Preservation Advisors LLC acquired a new stake in shares of Halozyme Therapeutics in the 1st quarter valued at approximately $32,000. SVB Wealth LLC acquired a new stake in shares of Halozyme Therapeutics in the 1st quarter valued at approximately $33,000. Bessemer Group Inc. lifted its holdings in shares of Halozyme Therapeutics by 62.9% in the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 207 shares during the period. Brooklyn Investment Group lifted its holdings in shares of Halozyme Therapeutics by 1,558.1% in the 1st quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 670 shares during the period. Finally, Park Place Capital Corp lifted its holdings in shares of Halozyme Therapeutics by 20.1% in the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock valued at $69,000 after buying an additional 182 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $69.03, for a total value of $1,380,600.00. Following the completion of the sale, the chief executive officer owned 733,719 shares of the company's stock, valued at $50,648,622.57. The trade was a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $75.24, for a total value of $150,480.00. Following the completion of the sale, the director directly owned 44,952 shares of the company's stock, valued at approximately $3,382,188.48. This represents a 4.26% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 108,227 shares of company stock valued at $7,779,595 over the last quarter. Company insiders own 2.90% of the company's stock.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $66.88 on Wednesday. The stock has a market cap of $7.82 billion, a price-to-earnings ratio of 15.30, a price-to-earnings-growth ratio of 0.36 and a beta of 1.16. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics, Inc. has a fifty-two week low of $42.01 and a fifty-two week high of $79.50. The business has a fifty day moving average of $71.69 and a 200-day moving average of $62.17.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, beating analysts' consensus estimates of $1.23 by $0.31. The business had revenue of $325.72 million during the quarter, compared to the consensus estimate of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The business's revenue for the quarter was up 40.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on HALO shares. Wall Street Zen cut Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, September 5th. Leerink Partners raised Halozyme Therapeutics from an "underperform" rating to a "market perform" rating and set a $70.00 price target for the company in a report on Tuesday, October 14th. JPMorgan Chase & Co. lifted their price objective on Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a "neutral" rating in a report on Thursday, August 7th. HC Wainwright reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a report on Tuesday. Finally, Weiss Ratings raised Halozyme Therapeutics from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $72.89.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.